863,721 Shares in Illumina, Inc. $ILMN Bought by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the first quarter, HoldingsChannel reports. The fund purchased 863,721 shares of the life sciences company’s stock, valued at approximately $106,462,000. Illumina accounts for approximately 1.1% of Vaughan Nelson Investment Management L.P.’s portfolio, making the stock its 25th largest holding.

Several other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. raised its position in Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after purchasing an additional 124,246 shares during the period. Elo Mutual Pension Insurance Co purchased a new position in Illumina during the third quarter worth $2,319,000. Capital World Investors boosted its stake in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the period. Nordea Investment Management AB lifted its holdings in Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Illumina during the 3rd quarter valued at about $1,827,000. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ILMN shares. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Royal Bank Of Canada assumed coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Barclays increased their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Finally, Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $142.12.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. The trade was a 7.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,003,154 shares of company stock worth $155,600,208. Corporate insiders own 2.90% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $161.93 on Monday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The stock has a market cap of $24.50 billion, a PE ratio of 29.44, a price-to-earnings-growth ratio of 3.03 and a beta of 1.50. The business has a 50-day simple moving average of $145.20 and a 200-day simple moving average of $136.21.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.